Improvements in clinical signs of Parkinson’s disease using photobiomodulation: a prospective proof-of-concept study
Background Parkinson’s disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging populations, longer disease duration and potentially as a COVID-19 sequela. Photobiomodulation (PBM) has been successfully used in animal mo...
Uloženo v:
| Vydáno v: | BMC neurology Ročník 21; číslo 1; s. 1 - 15 |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
BioMed Central
02.07.2021
BioMed Central Ltd Springer Nature B.V BMC |
| Témata: | |
| ISSN: | 1471-2377, 1471-2377 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background
Parkinson’s disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging populations, longer disease duration and potentially as a COVID-19 sequela. Photobiomodulation (PBM) has been successfully used in animal models to reduce the signs of PD and to protect dopaminergic neurons.
Objective
To assess the effectiveness of PBM to mitigate clinical signs of PD in a prospective proof-of-concept study, using a combination of transcranial and remote treatment, in order to inform on best practice for a larger randomized placebo-controlled trial (RCT).
Methods
Twelve participants with idiopathic PD were recruited. Six were randomly chosen to begin 12 weeks of transcranial, intranasal, neck and abdominal PBM. The remaining 6 were waitlisted for 14 weeks before commencing the same treatment. After the 12-week treatment period, all participants were supplied with PBM devices to continue home treatment. Participants were assessed for mobility, fine motor skills, balance and cognition before treatment began, after 4 weeks of treatment, after 12 weeks of treatment and the end of the home treatment period. A Wilcoxon Signed Ranks test was used to assess treatment effectiveness at a significance level of 5%.
Results
Measures of mobility, cognition, dynamic balance and fine motor skill were significantly improved (
p
< 0.05) with PBM treatment for 12 weeks and up to one year. Many individual improvements were above the minimal clinically important difference, the threshold judged to be meaningful for participants. Individual improvements varied but many continued for up to one year with sustained home treatment. There was a demonstrable Hawthorne Effect that was below the treatment effect. No side effects of the treatment were observed.
Conclusions
PBM was shown to be a safe and potentially effective treatment for a range of clinical signs and symptoms of PD. Improvements were maintained for as long as treatment continued, for up to one year in a neurodegenerative disease where decline is typically expected. Home treatment of PD by the person themselves or with the help of a carer might be an effective therapy option. The results of this study indicate that a large RCT is warranted.
Trial registration
Australian New Zealand Clinical Trials Registry, registration number:
ACTRN12618000038291p
, registered on 12/01/2018. |
|---|---|
| AbstractList | Parkinson's disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging populations, longer disease duration and potentially as a COVID-19 sequela. Photobiomodulation (PBM) has been successfully used in animal models to reduce the signs of PD and to protect dopaminergic neurons.BACKGROUNDParkinson's disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging populations, longer disease duration and potentially as a COVID-19 sequela. Photobiomodulation (PBM) has been successfully used in animal models to reduce the signs of PD and to protect dopaminergic neurons.To assess the effectiveness of PBM to mitigate clinical signs of PD in a prospective proof-of-concept study, using a combination of transcranial and remote treatment, in order to inform on best practice for a larger randomized placebo-controlled trial (RCT).OBJECTIVETo assess the effectiveness of PBM to mitigate clinical signs of PD in a prospective proof-of-concept study, using a combination of transcranial and remote treatment, in order to inform on best practice for a larger randomized placebo-controlled trial (RCT).Twelve participants with idiopathic PD were recruited. Six were randomly chosen to begin 12 weeks of transcranial, intranasal, neck and abdominal PBM. The remaining 6 were waitlisted for 14 weeks before commencing the same treatment. After the 12-week treatment period, all participants were supplied with PBM devices to continue home treatment. Participants were assessed for mobility, fine motor skills, balance and cognition before treatment began, after 4 weeks of treatment, after 12 weeks of treatment and the end of the home treatment period. A Wilcoxon Signed Ranks test was used to assess treatment effectiveness at a significance level of 5%.METHODSTwelve participants with idiopathic PD were recruited. Six were randomly chosen to begin 12 weeks of transcranial, intranasal, neck and abdominal PBM. The remaining 6 were waitlisted for 14 weeks before commencing the same treatment. After the 12-week treatment period, all participants were supplied with PBM devices to continue home treatment. Participants were assessed for mobility, fine motor skills, balance and cognition before treatment began, after 4 weeks of treatment, after 12 weeks of treatment and the end of the home treatment period. A Wilcoxon Signed Ranks test was used to assess treatment effectiveness at a significance level of 5%.Measures of mobility, cognition, dynamic balance and fine motor skill were significantly improved (p < 0.05) with PBM treatment for 12 weeks and up to one year. Many individual improvements were above the minimal clinically important difference, the threshold judged to be meaningful for participants. Individual improvements varied but many continued for up to one year with sustained home treatment. There was a demonstrable Hawthorne Effect that was below the treatment effect. No side effects of the treatment were observed.RESULTSMeasures of mobility, cognition, dynamic balance and fine motor skill were significantly improved (p < 0.05) with PBM treatment for 12 weeks and up to one year. Many individual improvements were above the minimal clinically important difference, the threshold judged to be meaningful for participants. Individual improvements varied but many continued for up to one year with sustained home treatment. There was a demonstrable Hawthorne Effect that was below the treatment effect. No side effects of the treatment were observed.PBM was shown to be a safe and potentially effective treatment for a range of clinical signs and symptoms of PD. Improvements were maintained for as long as treatment continued, for up to one year in a neurodegenerative disease where decline is typically expected. Home treatment of PD by the person themselves or with the help of a carer might be an effective therapy option. The results of this study indicate that a large RCT is warranted.CONCLUSIONSPBM was shown to be a safe and potentially effective treatment for a range of clinical signs and symptoms of PD. Improvements were maintained for as long as treatment continued, for up to one year in a neurodegenerative disease where decline is typically expected. Home treatment of PD by the person themselves or with the help of a carer might be an effective therapy option. The results of this study indicate that a large RCT is warranted.Australian New Zealand Clinical Trials Registry, registration number: ACTRN12618000038291p , registered on 12/01/2018.TRIAL REGISTRATIONAustralian New Zealand Clinical Trials Registry, registration number: ACTRN12618000038291p , registered on 12/01/2018. Abstract Background Parkinson’s disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging populations, longer disease duration and potentially as a COVID-19 sequela. Photobiomodulation (PBM) has been successfully used in animal models to reduce the signs of PD and to protect dopaminergic neurons. Objective To assess the effectiveness of PBM to mitigate clinical signs of PD in a prospective proof-of-concept study, using a combination of transcranial and remote treatment, in order to inform on best practice for a larger randomized placebo-controlled trial (RCT). Methods Twelve participants with idiopathic PD were recruited. Six were randomly chosen to begin 12 weeks of transcranial, intranasal, neck and abdominal PBM. The remaining 6 were waitlisted for 14 weeks before commencing the same treatment. After the 12-week treatment period, all participants were supplied with PBM devices to continue home treatment. Participants were assessed for mobility, fine motor skills, balance and cognition before treatment began, after 4 weeks of treatment, after 12 weeks of treatment and the end of the home treatment period. A Wilcoxon Signed Ranks test was used to assess treatment effectiveness at a significance level of 5%. Results Measures of mobility, cognition, dynamic balance and fine motor skill were significantly improved (p < 0.05) with PBM treatment for 12 weeks and up to one year. Many individual improvements were above the minimal clinically important difference, the threshold judged to be meaningful for participants. Individual improvements varied but many continued for up to one year with sustained home treatment. There was a demonstrable Hawthorne Effect that was below the treatment effect. No side effects of the treatment were observed. Conclusions PBM was shown to be a safe and potentially effective treatment for a range of clinical signs and symptoms of PD. Improvements were maintained for as long as treatment continued, for up to one year in a neurodegenerative disease where decline is typically expected. Home treatment of PD by the person themselves or with the help of a carer might be an effective therapy option. The results of this study indicate that a large RCT is warranted. Trial registration Australian New Zealand Clinical Trials Registry, registration number: ACTRN12618000038291p , registered on 12/01/2018. Background Parkinson’s disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging populations, longer disease duration and potentially as a COVID-19 sequela. Photobiomodulation (PBM) has been successfully used in animal models to reduce the signs of PD and to protect dopaminergic neurons. Objective To assess the effectiveness of PBM to mitigate clinical signs of PD in a prospective proof-of-concept study, using a combination of transcranial and remote treatment, in order to inform on best practice for a larger randomized placebo-controlled trial (RCT). Methods Twelve participants with idiopathic PD were recruited. Six were randomly chosen to begin 12 weeks of transcranial, intranasal, neck and abdominal PBM. The remaining 6 were waitlisted for 14 weeks before commencing the same treatment. After the 12-week treatment period, all participants were supplied with PBM devices to continue home treatment. Participants were assessed for mobility, fine motor skills, balance and cognition before treatment began, after 4 weeks of treatment, after 12 weeks of treatment and the end of the home treatment period. A Wilcoxon Signed Ranks test was used to assess treatment effectiveness at a significance level of 5%. Results Measures of mobility, cognition, dynamic balance and fine motor skill were significantly improved ( p < 0.05) with PBM treatment for 12 weeks and up to one year. Many individual improvements were above the minimal clinically important difference, the threshold judged to be meaningful for participants. Individual improvements varied but many continued for up to one year with sustained home treatment. There was a demonstrable Hawthorne Effect that was below the treatment effect. No side effects of the treatment were observed. Conclusions PBM was shown to be a safe and potentially effective treatment for a range of clinical signs and symptoms of PD. Improvements were maintained for as long as treatment continued, for up to one year in a neurodegenerative disease where decline is typically expected. Home treatment of PD by the person themselves or with the help of a carer might be an effective therapy option. The results of this study indicate that a large RCT is warranted. Trial registration Australian New Zealand Clinical Trials Registry, registration number: ACTRN12618000038291p , registered on 12/01/2018. Parkinson's disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging populations, longer disease duration and potentially as a COVID-19 sequela. Photobiomodulation (PBM) has been successfully used in animal models to reduce the signs of PD and to protect dopaminergic neurons. To assess the effectiveness of PBM to mitigate clinical signs of PD in a prospective proof-of-concept study, using a combination of transcranial and remote treatment, in order to inform on best practice for a larger randomized placebo-controlled trial (RCT). Twelve participants with idiopathic PD were recruited. Six were randomly chosen to begin 12 weeks of transcranial, intranasal, neck and abdominal PBM. The remaining 6 were waitlisted for 14 weeks before commencing the same treatment. After the 12-week treatment period, all participants were supplied with PBM devices to continue home treatment. Participants were assessed for mobility, fine motor skills, balance and cognition before treatment began, after 4 weeks of treatment, after 12 weeks of treatment and the end of the home treatment period. A Wilcoxon Signed Ranks test was used to assess treatment effectiveness at a significance level of 5%. Measures of mobility, cognition, dynamic balance and fine motor skill were significantly improved (p < 0.05) with PBM treatment for 12 weeks and up to one year. Many individual improvements were above the minimal clinically important difference, the threshold judged to be meaningful for participants. Individual improvements varied but many continued for up to one year with sustained home treatment. There was a demonstrable Hawthorne Effect that was below the treatment effect. No side effects of the treatment were observed. PBM was shown to be a safe and potentially effective treatment for a range of clinical signs and symptoms of PD. Improvements were maintained for as long as treatment continued, for up to one year in a neurodegenerative disease where decline is typically expected. Home treatment of PD by the person themselves or with the help of a carer might be an effective therapy option. The results of this study indicate that a large RCT is warranted. Background Parkinson's disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging populations, longer disease duration and potentially as a COVID-19 sequela. Photobiomodulation (PBM) has been successfully used in animal models to reduce the signs of PD and to protect dopaminergic neurons. Objective To assess the effectiveness of PBM to mitigate clinical signs of PD in a prospective proof-of-concept study, using a combination of transcranial and remote treatment, in order to inform on best practice for a larger randomized placebo-controlled trial (RCT). Methods Twelve participants with idiopathic PD were recruited. Six were randomly chosen to begin 12 weeks of transcranial, intranasal, neck and abdominal PBM. The remaining 6 were waitlisted for 14 weeks before commencing the same treatment. After the 12-week treatment period, all participants were supplied with PBM devices to continue home treatment. Participants were assessed for mobility, fine motor skills, balance and cognition before treatment began, after 4 weeks of treatment, after 12 weeks of treatment and the end of the home treatment period. A Wilcoxon Signed Ranks test was used to assess treatment effectiveness at a significance level of 5%. Results Measures of mobility, cognition, dynamic balance and fine motor skill were significantly improved (p < 0.05) with PBM treatment for 12 weeks and up to one year. Many individual improvements were above the minimal clinically important difference, the threshold judged to be meaningful for participants. Individual improvements varied but many continued for up to one year with sustained home treatment. There was a demonstrable Hawthorne Effect that was below the treatment effect. No side effects of the treatment were observed. Conclusions PBM was shown to be a safe and potentially effective treatment for a range of clinical signs and symptoms of PD. Improvements were maintained for as long as treatment continued, for up to one year in a neurodegenerative disease where decline is typically expected. Home treatment of PD by the person themselves or with the help of a carer might be an effective therapy option. The results of this study indicate that a large RCT is warranted. Trial registration Australian New Zealand Clinical Trials Registry, registration number: ACTRN12618000038291p, registered on 12/01/2018. Keywords: Parkinson's disease, Photobiomodulation, Cognition, Motor symptoms, Mobility Background Parkinson’s disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging populations, longer disease duration and potentially as a COVID-19 sequela. Photobiomodulation (PBM) has been successfully used in animal models to reduce the signs of PD and to protect dopaminergic neurons. Objective To assess the effectiveness of PBM to mitigate clinical signs of PD in a prospective proof-of-concept study, using a combination of transcranial and remote treatment, in order to inform on best practice for a larger randomized placebo-controlled trial (RCT). Methods Twelve participants with idiopathic PD were recruited. Six were randomly chosen to begin 12 weeks of transcranial, intranasal, neck and abdominal PBM. The remaining 6 were waitlisted for 14 weeks before commencing the same treatment. After the 12-week treatment period, all participants were supplied with PBM devices to continue home treatment. Participants were assessed for mobility, fine motor skills, balance and cognition before treatment began, after 4 weeks of treatment, after 12 weeks of treatment and the end of the home treatment period. A Wilcoxon Signed Ranks test was used to assess treatment effectiveness at a significance level of 5%. Results Measures of mobility, cognition, dynamic balance and fine motor skill were significantly improved (p < 0.05) with PBM treatment for 12 weeks and up to one year. Many individual improvements were above the minimal clinically important difference, the threshold judged to be meaningful for participants. Individual improvements varied but many continued for up to one year with sustained home treatment. There was a demonstrable Hawthorne Effect that was below the treatment effect. No side effects of the treatment were observed. Conclusions PBM was shown to be a safe and potentially effective treatment for a range of clinical signs and symptoms of PD. Improvements were maintained for as long as treatment continued, for up to one year in a neurodegenerative disease where decline is typically expected. Home treatment of PD by the person themselves or with the help of a carer might be an effective therapy option. The results of this study indicate that a large RCT is warranted. Trial registration Australian New Zealand Clinical Trials Registry, registration number: ACTRN12618000038291p, registered on 12/01/2018. |
| ArticleNumber | 256 |
| Audience | Academic |
| Author | Jalilitabaei, Parastoo Liebert, Ann Laakso, E-Liisa Heller, Gillian Tilley, Sharon Bicknell, Brian Mitrofanis, John Kiat, Hosen |
| Author_xml | – sequence: 1 givenname: Ann surname: Liebert fullname: Liebert, Ann email: ann.liebert@sydney.edu.au organization: School of Medical Sciences, University of Sydney, Governance and Research Department, Sydney Adventist Hospital – sequence: 2 givenname: Brian surname: Bicknell fullname: Bicknell, Brian organization: Faculty of Health Sciences, Australian Cathlic University – sequence: 3 givenname: E-Liisa surname: Laakso fullname: Laakso, E-Liisa organization: Mater Research Institute, Menzies Health Institute Queensland, Griffith University – sequence: 4 givenname: Gillian surname: Heller fullname: Heller, Gillian organization: NHMRC Clinical Trials Centre, University of Sydney, Department of Mathematics and Statistics, Macquarie University – sequence: 5 givenname: Parastoo surname: Jalilitabaei fullname: Jalilitabaei, Parastoo organization: Department of Anatomy, University of Sydney – sequence: 6 givenname: Sharon surname: Tilley fullname: Tilley, Sharon organization: Lymphoedema And Laser Therapy – sequence: 7 givenname: John surname: Mitrofanis fullname: Mitrofanis, John organization: Department of Anatomy, University of Sydney – sequence: 8 givenname: Hosen surname: Kiat fullname: Kiat, Hosen organization: Faculty of medicine, Health and Human Sciences, Macquarie University, Faculty of Medicine, University of NSW, Cardiac Health Institute |
| BookMark | eNp9Ustu1DAUjVARfcAPsLLEhk2Kn7HDAqmqeIxUCRawthzbST0kdoiTkWbHb_B7fAl3ZorKVKiyLV_b55zr-zgvTmKKviheEnxJiKreZEKVYiWmBBblqtw-Kc4Il6SkTMqTf-zT4jznNcZEKk6eFaeMUyIoqc6KzWoYp7Txg49zRiEi24cYrOlRDl3MKLXoi5m-h5hT_P3zV0YuZG-yR0sOsUPjbZpTE9KQ3NKbOaT4FhkEinn0dg4bv7NTW8K0KVo_zijPi9s-L562ps_-xd1-UXz78P7r9afy5vPH1fXVTWkrgeeypha3DW5I66iSNfaOwslS3vCWeSqJc5WQvGaNIaKyLXFMKAizrqwUXDbsolgddF0yaz1OYTDTVicT9P4iTZ020xxs7zV3FW4qZQSuay4kbURNm6rFxnsCfnZa7w5a49IM3lnI2GT6I9HjlxhudZc2WlFeQ75B4PWdwJR-LD7PegjZ-r430aclayq44hg-zgD66gF0nZYpQqoAJRgVSlX1PaozEECIbQK_dieqrypJGWE136Eu_4OC4fwQoCq-DXB_RFAHgoU65sm32oZ5X1wghl4TrHf9pw_9p6H_9L7_9Bao9AH1b3oeJbEDKQM4dn66D_YR1h9hevCc |
| CitedBy_id | crossref_primary_10_1089_neu_2022_0140 crossref_primary_10_3390_biomedicines11020237 crossref_primary_10_1186_s12967_023_03988_w crossref_primary_10_1007_s10103_025_04501_z crossref_primary_10_3389_fnins_2023_1268955 crossref_primary_10_3390_ijms25031625 crossref_primary_10_3390_medicina61071224 crossref_primary_10_59717_j_xinn_med_2023_100046 crossref_primary_10_59717_j_xinn_med_2024_100046 crossref_primary_10_1177_20595131221134052 crossref_primary_10_3389_fnins_2022_945796 crossref_primary_10_1002_14651858_CD012426_pub2 crossref_primary_10_1111_jnc_16145 crossref_primary_10_1515_revneuro_2023_0003 crossref_primary_10_3390_photonics9100686 crossref_primary_10_12677_tcm_2024_1311424 crossref_primary_10_1002_INMD_20240013 crossref_primary_10_1016_j_tjpad_2025_100185 crossref_primary_10_3389_fmed_2025_1555704 crossref_primary_10_3390_biomedicines11051497 crossref_primary_10_1111_acel_14005 crossref_primary_10_1007_s11357_024_01231_y crossref_primary_10_1186_s12984_024_01351_8 crossref_primary_10_1002_jbio_202200391 crossref_primary_10_3390_jcm14103402 crossref_primary_10_3390_jpm12010049 crossref_primary_10_1186_s12883_024_03857_z crossref_primary_10_3390_ijms24119577 crossref_primary_10_3390_ijms23148043 crossref_primary_10_1007_s43630_024_00613_7 crossref_primary_10_34172_jlms_2022_28 crossref_primary_10_4103_1673_5374_390970 crossref_primary_10_1016_j_plrev_2022_09_003 crossref_primary_10_1111_cns_70142 crossref_primary_10_3389_fnagi_2023_1151850 crossref_primary_10_1111_php_14060 crossref_primary_10_3389_fphar_2022_965788 crossref_primary_10_3390_healthcare12060676 crossref_primary_10_3390_jcm12082846 crossref_primary_10_3390_jpm14010112 crossref_primary_10_1111_ejn_15973 crossref_primary_10_1002_jbio_202300215 crossref_primary_10_1007_s10103_024_04198_6 crossref_primary_10_1007_s10103_025_04572_y crossref_primary_10_1016_j_niox_2022_11_005 crossref_primary_10_1016_j_heliyon_2024_e32800 crossref_primary_10_1016_j_buildenv_2024_111587 crossref_primary_10_1016_j_arr_2022_101786 crossref_primary_10_1016_j_jaad_2025_04_031 crossref_primary_10_1117_1_NPh_11_1_010601 crossref_primary_10_3390_brainsci14121164 crossref_primary_10_3390_nano14131093 crossref_primary_10_3389_fnins_2023_1247290 crossref_primary_10_3390_biom13071140 crossref_primary_10_3389_fnagi_2022_807909 crossref_primary_10_1007_s11357_025_01505_z crossref_primary_10_3233_ADR_230115 crossref_primary_10_1016_j_brainres_2023_148615 crossref_primary_10_1177_0271678X241311695 crossref_primary_10_3389_fmed_2022_1033486 crossref_primary_10_1016_j_arr_2024_102183 |
| Cites_doi | 10.1016/j.brs.2019.02.009 10.1016/S1474-4422(16)00066-1 10.1016/j.neuroscience.2019.10.037 10.1096/fj.201901917RR 10.1002/gps.5039 10.1080/08039488.2018.1468480 10.1002/mds.27602 10.1007/s40265-019-01098-w 10.1042/BIO03806024 10.1016/j.jbmt.2019.02.009 10.1016/j.humov.2010.08.008 10.1002/mds.27372 10.1111/php.12864 10.1117/1.NPh.3.3.031404 10.3934/biophy.2017.3.337 10.1117/1.NPh.3.1.015003 10.1007/s00415-019-09348-3 10.1016/S0166-2236(02)02181-1 10.2174/1389450115666140826104030 10.3138/ptc.48.4.257 10.1038/srep10581 10.1016/B978-0-12-815305-5.00033-6 10.4103/1673-5374.153673 10.1007/s10103-013-1356-8 10.1089/pho.2015.3988 10.1016/j.pneurobio.2018.09.003 10.1016/j.jocn.2018.10.043 10.1093/ptj/85.2.134 10.1589/jpts.27.3675 10.1123/jab.2013-0319 10.1038/s41598-019-42693-x 10.1111/j.1750-3639.2009.00369.x 10.1186/alzrt232 10.3233/JPD-202073 10.21767/2171-6625.1000176 10.4103/1673-5374.205092 10.1089/photob.2019.4685 10.1016/j.parkreldis.2010.08.012 10.1093/ptj/80.9.896 10.1089/neu.2013.3244 10.1016/j.pain.2006.05.018 10.1016/j.arr.2017.05.005 10.1590/s1980-5764-2016dn1004005 10.1089/photob.2018.4569 10.1080/13543784.2020.1771693 10.1016/0197-2456(89)90005-6 10.1093/arclin/acaa039 10.1007/s004150170047 10.1016/j.neuroscience.2018.12.050 10.1016/B978-0-12-815305-5.00042-7 10.1089/photob.2019.4663 10.1093/ptj/78.6.577 10.1007/s00221-017-5048-7 10.1007/s10103-019-02898-y 10.1097/NPT.0b013e318235da08 10.1002/mds.27779 10.1016/j.mehy.2013.12.009 10.5694/mja17.00993 10.1016/S1474-4422(18)30355-7 10.1089/pho.2016.4227 10.1179/016164107X251772 10.4103/1673-5374.262573 10.1038/s41583-019-0257-7 10.1089/pho.2018.4527 10.1002/mds.870131315 10.1016/j.jclinepi.2013.08.015 10.1016/j.jphotobiol.2020.111916 10.1016/j.parkreldis.2019.08.010 10.1136/bmjopen-2011-000628 10.1002/mds.22017 10.1002/cne.22207 10.3233/JPD-181477 10.1002/mds.27790 10.1093/ptj/81.2.810 10.3390/biom10040610 10.1089/photob.2019.4678 10.1097/01.MLR.0000064706.35861.B4 10.1186/s12938-020-00776-1 10.1519/JPT.0000000000000068 10.1097/01.MLR.0000062554.74615.4C 10.2147/IJGM.S65803 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2021 – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION 3V. 7TK 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12883-021-02248-y |
| DatabaseName | Springer Nature OA Free Journals CrossRef ProQuest Central (Corporate) Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central Korea Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2377 |
| EndPage | 15 |
| ExternalDocumentID | oai_doaj_org_article_4d60b68a50994572b592b6f0aee11ddb PMC8249215 A672313949 10_1186_s12883_021_02248_y |
| GeographicLocations | Australia |
| GeographicLocations_xml | – name: Australia |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABIVO ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IGS IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION 3V. 7TK 7XB 8FK AZQEC COVID DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c650t-92c0fb0b1fd28790ed2b0bc24b4f3e271dd657493ba156cf1d35800196c7547b3 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 72 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000671838300003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1471-2377 |
| IngestDate | Mon Nov 10 04:32:01 EST 2025 Tue Nov 04 02:01:30 EST 2025 Sun Nov 09 11:39:54 EST 2025 Thu Oct 09 21:40:34 EDT 2025 Tue Nov 11 10:28:33 EST 2025 Tue Nov 04 17:54:53 EST 2025 Sat Nov 29 01:40:00 EST 2025 Tue Nov 18 21:41:20 EST 2025 Sat Sep 06 07:35:55 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Mobility Cognition Parkinson’s disease Photobiomodulation Motor symptoms |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c650t-92c0fb0b1fd28790ed2b0bc24b4f3e271dd657493ba156cf1d35800196c7547b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://link.springer.com/10.1186/s12883-021-02248-y |
| PMID | 34215216 |
| PQID | 2553258869 |
| PQPubID | 44772 |
| PageCount | 15 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_4d60b68a50994572b592b6f0aee11ddb pubmedcentral_primary_oai_pubmedcentral_nih_gov_8249215 proquest_miscellaneous_2548407543 proquest_journals_2553258869 gale_infotracmisc_A672313949 gale_infotracacademiconefile_A672313949 crossref_citationtrail_10_1186_s12883_021_02248_y crossref_primary_10_1186_s12883_021_02248_y springer_journals_10_1186_s12883_021_02248_y |
| PublicationCentury | 2000 |
| PublicationDate | 2021-07-02 |
| PublicationDateYYYYMMDD | 2021-07-02 |
| PublicationDate_xml | – month: 07 year: 2021 text: 2021-07-02 day: 02 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London |
| PublicationTitle | BMC neurology |
| PublicationTitleAbbrev | BMC Neurol |
| PublicationYear | 2021 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | AF Barbosa (2248_CR51) 2016; 10 BM Morberg (2248_CR75) 2018; 72 P Benson (2248_CR9) 2020; 208 SH Fox (2248_CR5) 2018; 33 AF Mazancova (2248_CR54) 2020; 35 AS Chan (2248_CR56) 2019; 34 SL Pullman (2248_CR34) 1998; 13 P Cassano (2248_CR12) 2019; 37 LJ Evers (2248_CR62) 2019; 34 MV Pires de Sousa (2248_CR18) 2016; 3 Z Al Amir Dache (2248_CR87) 2020; 34 F Smithson (2248_CR36) 1998; 78 A Grünewald (2248_CR4) 2019; 177 R Zomorrodi (2248_CR82) 2019; 9 S-E Soh (2248_CR46) 2011; 17 D Aarsland (2248_CR53) 2010; 20 J Mitrofanis (2248_CR22) 2017; 12 K Brusse (2248_CR63) 2005; 85 F Salehpour (2248_CR19) 2020; 10 RT Chow (2248_CR69) 2006; 124 WJ Choi (2248_CR77) 2019; 96 J Stone (2248_CR26) 2013 AL Johnston (2248_CR81) 2009 P Cassano (2248_CR85) 2016; 3 S Holroyd (2248_CR64) 2008; 30 R de la Fuente-Fernández (2248_CR72) 2002; 25 F Salehpour (2248_CR58) 2019; 37 GR Norman (2248_CR37) 2003; 41 G Christofoletti (2248_CR52) 2014; 7 V Ganeshan (2248_CR24) 2019; 400 A Liebert (2248_CR68) 2018; 36 A Regnault (2248_CR61) 2019; 266 M Parmar (2248_CR45) 2020; 21 F Scheperjans (2248_CR6) 2018; 8 GM Earhart (2248_CR35) 2011; 35 LC Gordon (2248_CR25) 2019; 14 AE Saltmarche (2248_CR59) 2017; 35 B Kim (2248_CR23) 2017; 37 BR Bloem (2248_CR49) 2001; 248 MA Naeser (2248_CR55) 2014; 31 M Lubomski (2248_CR7) 2019; 66 V Robles-García (2248_CR76) 2015; 31 WA Rocca (2248_CR1) 2018; 17 H El Khoury (2248_CR83) 2019; 422 LC Beauchamp (2248_CR2) 2020; Preprint R Jaeschke (2248_CR66) 1989; 10 2248_CR84 S Purushothuman (2248_CR21) 2014; 6 MR Hamblin (2248_CR14) 2017; 4 N Titova (2248_CR39) 2018; 208 F Benedetti (2248_CR74) 2016; 15 2248_CR80 MH Berman (2248_CR57) 2017; 8 L Santos (2248_CR27) 2019; 12 S Morris (2248_CR47) 2001; 81 C Bidet-Ildei (2248_CR71) 2011; 30 K Seppi (2248_CR41) 2019; 34 J McCambridge (2248_CR73) 2014; 67 DM Johnstone (2248_CR15) 2015; 10 N Paker (2248_CR48) 2015; 27 AAM Lima (2248_CR86) 2014; 29 MR Hamblin (2248_CR8) 2018; 94 CL Hamilton (2248_CR28) 2019; 37 F Lauretani (2248_CR40) 2014; 15 C Moro (2248_CR11) 2017; 235 S Moosa (2248_CR43) 2019; 34 KB Foreman (2248_CR78) 2013; 2013 DJ Gill (2248_CR33) 2008; 23 M Fleischmann (2248_CR65) 2019; 23 A Blatt (2248_CR17) 2016; 34 A Liebert (2248_CR16) 2014; 82 A Shumway-Cook (2248_CR30) 2000; 80 AW Shukla (2248_CR70) 2012; 2 I Khan (2248_CR10) 2015; 5 MR Hamblin (2248_CR13) 2016; 38 MH Berman (2248_CR29) 2019; 37 V Cabreira (2248_CR38) 2019; 79 A Antonini (2248_CR44) 2020; 29 HL Casalechi (2248_CR79) 2020; 35 C Brooks (2248_CR60) 2019; 61 V Shaw (2248_CR20) 2010; 518 JT Lang (2248_CR31) 2016; 39 DB Victorino (2248_CR3) 2020; 10 K Hill (2248_CR32) 1996; 47 DE Beaton (2248_CR67) 2003; 41 Z Rahmati (2248_CR50) 2020; 19 S Bratsos (2248_CR42) 2018; 10 |
| References_xml | – volume: 12 start-page: 810 issue: 3 year: 2019 ident: 2248_CR27 publication-title: Brain Stimul doi: 10.1016/j.brs.2019.02.009 – volume: 15 start-page: 736 issue: 7 year: 2016 ident: 2248_CR74 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(16)00066-1 – volume: 422 start-page: 161 year: 2019 ident: 2248_CR83 publication-title: Neuroscience. doi: 10.1016/j.neuroscience.2019.10.037 – volume: 34 start-page: 3616 issue: 3 year: 2020 ident: 2248_CR87 publication-title: FASEB J doi: 10.1096/fj.201901917RR – volume: 34 start-page: 369 issue: 2 year: 2019 ident: 2248_CR56 publication-title: Int J Geriatr Psychiatry doi: 10.1002/gps.5039 – volume: 72 start-page: 442 issue: 6 year: 2018 ident: 2248_CR75 publication-title: Nordic J Psychiatry doi: 10.1080/08039488.2018.1468480 – volume: 34 start-page: 180 issue: 2 year: 2019 ident: 2248_CR41 publication-title: Mov Disord doi: 10.1002/mds.27602 – volume: 79 start-page: 593 issue: 6 year: 2019 ident: 2248_CR38 publication-title: Drugs. doi: 10.1007/s40265-019-01098-w – volume: 38 start-page: 24 issue: 6 year: 2016 ident: 2248_CR13 publication-title: Biochemist doi: 10.1042/BIO03806024 – volume: 23 start-page: 690 issue: 4 year: 2019 ident: 2248_CR65 publication-title: J Bodyw Mov Ther doi: 10.1016/j.jbmt.2019.02.009 – volume: 10 start-page: e3474 issue: 10 year: 2018 ident: 2248_CR42 publication-title: Cureus – volume: 30 start-page: 783 issue: 4 year: 2011 ident: 2248_CR71 publication-title: Hum Mov Sci doi: 10.1016/j.humov.2010.08.008 – volume: 33 start-page: 1248 issue: 8 year: 2018 ident: 2248_CR5 publication-title: Mov Disord doi: 10.1002/mds.27372 – volume: 94 start-page: 199 issue: 2 year: 2018 ident: 2248_CR8 publication-title: Photochem Photobiol doi: 10.1111/php.12864 – volume: 3 start-page: 031404 issue: 3 year: 2016 ident: 2248_CR85 publication-title: Neurophotonics. doi: 10.1117/1.NPh.3.3.031404 – volume: 4 start-page: 337 issue: 3 year: 2017 ident: 2248_CR14 publication-title: AIMS Biophys doi: 10.3934/biophy.2017.3.337 – volume: 3 start-page: 015003 issue: 1 year: 2016 ident: 2248_CR18 publication-title: Neurophotonics doi: 10.1117/1.NPh.3.1.015003 – volume: 266 start-page: 1927 issue: 8 year: 2019 ident: 2248_CR61 publication-title: J Neurol doi: 10.1007/s00415-019-09348-3 – volume: 25 start-page: 302 issue: 6 year: 2002 ident: 2248_CR72 publication-title: Trends Neurosci doi: 10.1016/S0166-2236(02)02181-1 – volume: 15 start-page: 943 issue: 10 year: 2014 ident: 2248_CR40 publication-title: Curr Drug Targets doi: 10.2174/1389450115666140826104030 – volume: 47 start-page: 257 year: 1996 ident: 2248_CR32 publication-title: Physiother Can doi: 10.3138/ptc.48.4.257 – volume: 5 start-page: 10581 issue: 1 year: 2015 ident: 2248_CR10 publication-title: Sci Rep doi: 10.1038/srep10581 – ident: 2248_CR84 doi: 10.1016/B978-0-12-815305-5.00033-6 – volume: 10 start-page: 349 issue: 3 year: 2015 ident: 2248_CR15 publication-title: Neural Regen Res doi: 10.4103/1673-5374.153673 – volume: 29 start-page: 709 issue: 2 year: 2014 ident: 2248_CR86 publication-title: Lasers Med Sci doi: 10.1007/s10103-013-1356-8 – volume: 34 start-page: 516 issue: 11 year: 2016 ident: 2248_CR17 publication-title: Photomed Laser Surg doi: 10.1089/pho.2015.3988 – volume: 177 start-page: 73 year: 2019 ident: 2248_CR4 publication-title: Prog Neurobiol doi: 10.1016/j.pneurobio.2018.09.003 – volume: 61 start-page: 174 year: 2019 ident: 2248_CR60 publication-title: J Clin Neurosci doi: 10.1016/j.jocn.2018.10.043 – volume: 85 start-page: 134 issue: 2 year: 2005 ident: 2248_CR63 publication-title: Phys Ther doi: 10.1093/ptj/85.2.134 – volume: 27 start-page: 3675 issue: 12 year: 2015 ident: 2248_CR48 publication-title: J Phys Ther Sci doi: 10.1589/jpts.27.3675 – volume: 31 start-page: 189 issue: 3 year: 2015 ident: 2248_CR76 publication-title: J Appl Biomech doi: 10.1123/jab.2013-0319 – volume: 9 start-page: 1 issue: 1 year: 2019 ident: 2248_CR82 publication-title: Sci Rep doi: 10.1038/s41598-019-42693-x – volume: 20 start-page: 633 issue: 3 year: 2010 ident: 2248_CR53 publication-title: Brain Pathol doi: 10.1111/j.1750-3639.2009.00369.x – volume: 96 start-page: 21 issue: 2 year: 2019 ident: 2248_CR77 publication-title: Univ Tor Med J – volume: 6 start-page: 2 issue: 1 year: 2014 ident: 2248_CR21 publication-title: Alzheimers Res Ther doi: 10.1186/alzrt232 – volume: 10 start-page: 899 issue: 3 year: 2020 ident: 2248_CR3 publication-title: J Parkinsons Dis doi: 10.3233/JPD-202073 – volume: 8 start-page: 176 issue: 1 year: 2017 ident: 2248_CR57 publication-title: J Neurol Neurosci doi: 10.21767/2171-6625.1000176 – volume: 12 start-page: 574 issue: 4 year: 2017 ident: 2248_CR22 publication-title: Neural Regen Res doi: 10.4103/1673-5374.205092 – volume: 37 start-page: 623 issue: 10 year: 2019 ident: 2248_CR29 publication-title: Photobiomodul Photomed Laser Surg. doi: 10.1089/photob.2019.4685 – volume: 17 start-page: 1 issue: 1 year: 2011 ident: 2248_CR46 publication-title: Parkinsonism Relat Disord doi: 10.1016/j.parkreldis.2010.08.012 – volume: 80 start-page: 896 issue: 9 year: 2000 ident: 2248_CR30 publication-title: Phys Ther doi: 10.1093/ptj/80.9.896 – volume: 31 start-page: 1008 issue: 11 year: 2014 ident: 2248_CR55 publication-title: J Neurotrauma doi: 10.1089/neu.2013.3244 – volume: 124 start-page: 201 issue: 1–2 year: 2006 ident: 2248_CR69 publication-title: Pain. doi: 10.1016/j.pain.2006.05.018 – volume: 37 start-page: 69 year: 2017 ident: 2248_CR23 publication-title: Ageing Res Rev doi: 10.1016/j.arr.2017.05.005 – volume: 10 start-page: 280 issue: 4 year: 2016 ident: 2248_CR51 publication-title: Dement Neuropsychol doi: 10.1590/s1980-5764-2016dn1004005 – volume: 37 start-page: 159 issue: 3 year: 2019 ident: 2248_CR58 publication-title: Photobiomodul Photomed Laser Surg doi: 10.1089/photob.2018.4569 – volume: 29 start-page: 685 issue: 7 year: 2020 ident: 2248_CR44 publication-title: Expert Opin Investig Drugs doi: 10.1080/13543784.2020.1771693 – volume: 10 start-page: 407 issue: 4 year: 1989 ident: 2248_CR66 publication-title: Control Clin Trials doi: 10.1016/0197-2456(89)90005-6 – volume: 35 start-page: 1069 issue: 7 year: 2020 ident: 2248_CR54 publication-title: Arch Clin Neuropsychol doi: 10.1093/arclin/acaa039 – volume: 248 start-page: 950 issue: 11 year: 2001 ident: 2248_CR49 publication-title: J Neurol doi: 10.1007/s004150170047 – volume: 400 start-page: 85 year: 2019 ident: 2248_CR24 publication-title: Neuroscience doi: 10.1016/j.neuroscience.2018.12.050 – ident: 2248_CR80 doi: 10.1016/B978-0-12-815305-5.00042-7 – volume: 37 start-page: 615 issue: 10 year: 2019 ident: 2248_CR28 publication-title: Photobiomodul Photomed Laser Surg doi: 10.1089/photob.2019.4663 – volume-title: Psychological benefits 2 and 4 weeks after a single treatment with near infrared light to the forehead: a pilot study of 10 patients with major depression and anxiety year: 2009 ident: 2248_CR81 – volume: Preprint start-page: 1 year: 2020 ident: 2248_CR2 publication-title: J Parkinson's Dis – volume-title: The helmet experiment in Parkinson's disease: an observation of the mechanism of neuroprotection by near infra-red light year: 2013 ident: 2248_CR26 – volume: 78 start-page: 577 issue: 6 year: 1998 ident: 2248_CR36 publication-title: Phys Ther doi: 10.1093/ptj/78.6.577 – volume: 235 start-page: 3081 issue: 10 year: 2017 ident: 2248_CR11 publication-title: Exp Brain Res doi: 10.1007/s00221-017-5048-7 – volume: 35 start-page: 1253 issue: 6 year: 2020 ident: 2248_CR79 publication-title: Lasers Med Sci doi: 10.1007/s10103-019-02898-y – volume: 35 start-page: 157 issue: 4 year: 2011 ident: 2248_CR35 publication-title: J Neurol Phys Ther doi: 10.1097/NPT.0b013e318235da08 – volume: 34 start-page: 1243 issue: 9 year: 2019 ident: 2248_CR43 publication-title: Mov Disord doi: 10.1002/mds.27779 – volume: 2013 start-page: 987621 year: 2013 ident: 2248_CR78 publication-title: Parkinson’s Dis – volume: 82 start-page: 275 issue: 3 year: 2014 ident: 2248_CR16 publication-title: Med Hypotheses doi: 10.1016/j.mehy.2013.12.009 – volume: 208 start-page: 404 issue: 9 year: 2018 ident: 2248_CR39 publication-title: Med J Aust doi: 10.5694/mja17.00993 – volume: 17 start-page: 928 issue: 11 year: 2018 ident: 2248_CR1 publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(18)30355-7 – volume: 35 start-page: 432 issue: 8 year: 2017 ident: 2248_CR59 publication-title: Photomed Laser Surg doi: 10.1089/pho.2016.4227 – volume: 30 start-page: 493 issue: 5 year: 2008 ident: 2248_CR64 publication-title: Neurol Res doi: 10.1179/016164107X251772 – volume: 14 start-page: 2086 issue: 12 year: 2019 ident: 2248_CR25 publication-title: Neural Regen Res doi: 10.4103/1673-5374.262573 – volume: 21 start-page: 103 issue: 2 year: 2020 ident: 2248_CR45 publication-title: Nat Rev Neurosci doi: 10.1038/s41583-019-0257-7 – volume: 36 start-page: 515 issue: 10 year: 2018 ident: 2248_CR68 publication-title: Photomed Laser Surg doi: 10.1089/pho.2018.4527 – volume: 13 start-page: 85 issue: S3 year: 1998 ident: 2248_CR34 publication-title: Mov Disord doi: 10.1002/mds.870131315 – volume: 67 start-page: 267 issue: 3 year: 2014 ident: 2248_CR73 publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2013.08.015 – volume: 208 start-page: 111916 year: 2020 ident: 2248_CR9 publication-title: J Photochem Photobiol B Biol doi: 10.1016/j.jphotobiol.2020.111916 – volume: 66 start-page: 265 year: 2019 ident: 2248_CR7 publication-title: Parkinsonism Relat Disord doi: 10.1016/j.parkreldis.2019.08.010 – volume: 2 start-page: e000628 issue: 3 year: 2012 ident: 2248_CR70 publication-title: BMJ Open doi: 10.1136/bmjopen-2011-000628 – volume: 23 start-page: 1043 issue: 7 year: 2008 ident: 2248_CR33 publication-title: Mov Disord doi: 10.1002/mds.22017 – volume: 518 start-page: 25 issue: 1 year: 2010 ident: 2248_CR20 publication-title: J Comp Neurol doi: 10.1002/cne.22207 – volume: 8 start-page: S31 issue: s1 year: 2018 ident: 2248_CR6 publication-title: J Parkinsons Dis doi: 10.3233/JPD-181477 – volume: 34 start-page: 1480 issue: 10 year: 2019 ident: 2248_CR62 publication-title: Mov Disord doi: 10.1002/mds.27790 – volume: 81 start-page: 810 issue: 2 year: 2001 ident: 2248_CR47 publication-title: Phys Ther doi: 10.1093/ptj/81.2.810 – volume: 10 start-page: 610 issue: 4 year: 2020 ident: 2248_CR19 publication-title: Biomolecules. doi: 10.3390/biom10040610 – volume: 37 start-page: 651 issue: 10 year: 2019 ident: 2248_CR12 publication-title: Photobiomodul Photomed Laser Surg. doi: 10.1089/photob.2019.4678 – volume: 41 start-page: 593 issue: 5 year: 2003 ident: 2248_CR67 publication-title: Med Care doi: 10.1097/01.MLR.0000064706.35861.B4 – volume: 19 start-page: 1 year: 2020 ident: 2248_CR50 publication-title: Biomed Eng Online doi: 10.1186/s12938-020-00776-1 – volume: 39 start-page: 165 issue: 4 year: 2016 ident: 2248_CR31 publication-title: J Geriatr Phys Ther doi: 10.1519/JPT.0000000000000068 – volume: 41 start-page: 582 issue: 5 year: 2003 ident: 2248_CR37 publication-title: Med Care doi: 10.1097/01.MLR.0000062554.74615.4C – volume: 7 start-page: 383 year: 2014 ident: 2248_CR52 publication-title: Int J Gen Med doi: 10.2147/IJGM.S65803 |
| SSID | ssj0017841 |
| Score | 2.5314066 |
| Snippet | Background
Parkinson’s disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging... Background Parkinson's disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging... Parkinson's disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging... Background Parkinson’s disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due to aging... Abstract Background Parkinson’s disease (PD) is a progressive neurodegenerative disease with no cure and few treatment options. Its incidence is increasing due... |
| SourceID | doaj pubmedcentral proquest gale crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 1 |
| SubjectTerms | Aging Alzheimer's disease Animal models Brain research Care and treatment Clinical trials Cognition COVID-19 Dopamine receptors Ethics Laser therapy Lasers Light therapy Medicine Medicine & Public Health Mobility Motor skill Motor symptoms Movement disorders Neurochemistry Neurodegenerative diseases Neurology Neurosurgery Parkinson's disease Photobiomodulation Phototherapy Placebos Testing Therapy |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQhRAXxFMECjISEgewGieOHXMriIoDVBwA9WbFL7oSJFWzrdQbf6N_r7-EGcdZCBVwQdrD7tp5zcOeycx8Q8jTziurVJBMah2YkCKCzrUN45XU0SpZ1ql92-d3an-_PTjQH35p9YU5YRM88ES4HeFlaWXbwcamRaMq2-jKylh2IXDuvcXVF6ye2ZnK8QOMps0lMq3cGTk21WWYjoB7VsvOFttQQuu_vCZfzpP8LVia9qC9m-RGNh7p7nTTt8iV0N8m197n8Pgdcjq9Ikhv_Ea66ulc90gxTWOkQ6RY5ZwKvi6-n480h2coZr9_oUeHwxpRmb4NPjf1ekk7CmecyzHx-xAZfNxU7UgTOu1d8mnvzcfXb1lurMAcGGRrpitXRltaHj04TLoMvoJfrhJWxDpUCugqGyV0bTtw71zkHoOliKTjVCOUre-RrX7ow31CgZ-883A2G4Tw4G45MImkKgP4McGJpiB8prNxGXUcm198Ncn7aKWZeGOANybxxpwV5PnmmKMJc-Ovs18h-zYzES87_QFSZLIUmX9JUUGeIfMNajXcnutycQI8JOJjmV2pwBCutdAF2V7MBG10y-FZfExeDUYDbltdNW0rYfjJZhiPxAy3PgwnOEeArw3krQuiFmK3eLLlSL86TIjgLeI-ciD2i1lAf178z5R78D8o95Bcr5JeKVCtbbK1Pj4Jj8hVd7pejcePk1b-AALvPRY priority: 102 providerName: Directory of Open Access Journals – databaseName: Publicly Available Content Database dbid: PIMPY link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZgixAX3hWBgoyExAGizcOx416qgqhAotUeAJWTFT_SrtQmy2ZbqTf-Bn-PX8KM42wVKnpC2sPu2nnYnhnPeGa-IeRVZYUWwvGYS-lixlkNPFcWcZpxWWvBk9yXb_v2WRwclIeHchbSo7sQVjnIRC-oe7RnjNsGITy1rcET8ykownlWlCWXO4sfMdaQQl9rKKhxk2wg8FY5IRuzT_uz72uvAvrYhsSZkk-7FEvtxhikgDtZGV-MNieP4X9VUl-NnvzLhep3pr17_3dM98ndoKHS3Z6kHpAbrnlIbu8HH_wjct6fQ_hjxY7OGzokV1KMBeloW1NMpfZZZb9__upo8AFRDLE_oovjdoXQT6etDZXDtmlF4Y5Dzid-b-sYPqZPqaQeAvcx-br34cv7j3Go3hAb0PpWscxMUutEp7UFq0wmzmbwy2RMszp3mUit5YVgMtcV2JCmTi16ZBGux4iCCZ1vkknTNu4JoUA0aWXhbtoxZsGmM6B3cZE4MJacYUVE0mHZlAnQ5lhh40R5E6fkql9qBUut_FKri4i8WV-z6IE9ru39Dqlh3RNBuf0f7fJIBR5XzPJE87ICHUyyQmS6kJnmdVI5l8JodUReIy0pFB3weqYKGRAwSAThUrtcgLadSyYjsjXqCSxvxs0DPakgcjp1ST4RebluxisxjK5x7Rn2YWDQw_TmEREjKh6NbNzSzI897HiJ4JIpTPbbgd4vH_7vmXt6_bs-I3cyz4ACeHCLTFbLM_ec3DLnq3m3fBEY-A-v1Fgx priority: 102 providerName: ProQuest |
| Title | Improvements in clinical signs of Parkinson’s disease using photobiomodulation: a prospective proof-of-concept study |
| URI | https://link.springer.com/article/10.1186/s12883-021-02248-y https://www.proquest.com/docview/2553258869 https://www.proquest.com/docview/2548407543 https://pubmed.ncbi.nlm.nih.gov/PMC8249215 https://doaj.org/article/4d60b68a50994572b592b6f0aee11ddb |
| Volume | 21 |
| WOSCitedRecordID | wos000671838300003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health Medical collection customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1471-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017841 issn: 1471-2377 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9RAEF9sK-KL32K0HisIPmgwH5v98K2VFgV7HFXL-bRkP9IeaFIu10Lf_Df89_xLnNkkJ7EqKIQjud1NspOZ3Z2dmd8Q8rR0wgjhecyV8jHjrAKZk0WcZlxVRvAkD-nbjt6J6VTO52rWB4W1g7f7YJIMI3UQa8lftikmxo3RpQDnHRlfbJAtmO4kiuPh-6O17QAtaUN4zG_bjaaggNR_eTy-7CP5i6E0zD_7N__vzW-RG_16k-50DHKbXPH1HXLtoLeo3yXn3a5C2CRs6aKmQ6gkRc-OljYVxcDoECP2_eu3lvYWHYoO88f09KRZIZDTl8b1ecBe0ZLCHYcITjxvqhgO2wVI0gBoe4983N_78PpN3OdiiC2s4VaxymxSmcSklQMdSyXeZXBlM2ZYlftMpM7xQjCVmxI0QlulDu2rCL5jRcGEye-Tzbqp_QNCgQXS0sHdjGfMgYZmYRXFReJB9fGWFRFJh8-jbQ9UjvkyPuugsEiuO4JqIKgOBNUXEXm-bnPawXT8tfYufvV1TYTYDn80y2PdS6xmjieGyxJYTLFCZKZQmeFVUnqfQm9NRJ4hz2gcCOD1bNnHM0AnEVJL73ABa-dcMRWR7VFNEGA7Lh64TvcDSKtB08uzQkoOxU_WxdgSneJq35xhHQbqOZA3j4gYceuoZ-OSenESQMQlQkWmQOwXA8_-fPifKffw36o_ItezwPYCOH-bbK6WZ_4xuWrPV4t2OSEbYi7Cr5yQrd296exwEvZE4Gr29mD2aRIE-we-kEgS |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKQcCFNyJQwEggDjRqHo4dIyFUHlWrblccCtqbiR9pV4Jk2WyL9sbf4E_wo_glzDjJVktFbz0g7SG7dryx8814xvMi5GlhhRbC8ZBL6ULGWQk0l2dhnHBZasGj1Jdv-zQQw2E-GskPK-RXHwuDbpU9T_SM2tYGz8g3QPRNkyzPuXw9-RZi1Si0rvYlNFpY7Lr5d1DZmlc77-D9PkuSrff7b7fDrqpAaEAamYUyMVGpIx2XFrQFGTmbwDeTMM3K1CUitpZngslUF6DbmDK2aCnENDJGZEzoFMa9QC4CHxfoQiZGCwUvRhteH5iT840mxlK-ITpB4E6Zh_Olzc_XCDi9E5z2zvzLROt3vq3r_9ua3SDXOhmbbrZEcZOsuOoWubzXeRHcJsftSYo_GG3ouKJ9eChFb5aG1iXFYHAfF_f7x8-GdlYsikECB3RyWM8wedXX2na1z17SgsKIfdQqXtdlCB_TBoVSn8T3Dvl4LrO-S1arunL3CAXYx4WF0bRjzIJWakBy5CJyoO45w7KAxD0wlOmSs2ONkC_KK2k5Vy2YFIBJeTCpeUBeLO6ZtKlJzuz9BvG26Ilpxf0P9fRAdVxKMcsjzfMCpEjJMpHoTCaal1HhXAyz1QF5jmhVyPzg8UzRxXDAJDGNmNrkAvSFVDIZkLWlnsC0zHJzj1jVMc1GncA1IE8WzXgnOgJWrj7CPixnIOayNCBiiU6WZrbcUo0PfeL0HNNjxrDY6z1Fnfz5v1fu_tnP-phc2d7fG6jBznD3AbmaeHIXQPFrZHU2PXIPySVzPBs300eeWVDy-bwp7Q_GLacN |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagoIoLb0SggJGQOEDUPBw75lYeKxBlVQmoerPiV7sSJKtNWqk3_gZ_j1_CjJMshAISQtrD7nqcrGdn7JnMzDeEPKqs0EI4HnMpXcw486BzZRGnGZdeC57koX3b_q6Yz8uDA7n3UxV_yHYfQ5J9TQOiNNXd9tL6XsVLvt2m2CQ3xvQCPIPK-PQ8ucCwaRD66-_313EEjKqNpTK_nTc5jgJq_9m9-Wy-5C9B03AWza78_yquksuDHUp3esG5Rs65-jrZfDdE2m-Qk_5pQ3h42NJFTccSSooZHy1tPMWC6VA79u3L15YOkR6KifSHdHnUdAjw9LmxQ3-wZ7SicMWxshPfNz6Gl-kLJ2kAur1JPs5efXjxOh56NMQGbLsulplJvE506i34XjJxNoNPJmOa-dxlIrWWF4LJXFfgKRqfWoy7IiiPEQUTOr9FNuqmdrcJBdFIKwtX044xC56bAeuKi8SBS-QMKyKSjn-VMgOAOfbR-KSCI1Ny1TNUAUNVYKg6jciT9ZxlD9_xV-rnKAFrSoTeDl80q0M1aLJiliealxVYWpIVItOFzDT3SeVcCqvVEXmM8qNwg4CfZ6qhzgEWiVBbaocLsKlzyWREtiaUoNhmOjxKoBo2llaBB5hnRVlyGH64HsaZmCxXu-YYaRi47cDePCJiIrmTlU1H6sVRABcvEUIyBWY_HeX3x83_zLk7_0b-gGzuvZyp3Tfzt3fJpSxogAAl2CIb3erY3SMXzUm3aFf3gzZ_B_pNTco |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Improvements+in+clinical+signs+of+Parkinson%27s+disease+using+photobiomodulation%3A+a+prospective+proof-of-concept+study&rft.jtitle=BMC+neurology&rft.au=Liebert%2C+Ann&rft.au=Bicknell%2C+Brian&rft.au=Laakso%2C+E-Liisa&rft.au=Heller%2C+Gillian&rft.date=2021-07-02&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2377&rft.eissn=1471-2377&rft.volume=21&rft.issue=1&rft_id=info:doi/10.1186%2Fs12883-021-02248-y&rft.externalDocID=A672313949 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2377&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2377&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2377&client=summon |